Skip to Main Content
Try STAT+ TODAY
Trending:
The Obesity Revolution
Health
Biotech
STAT+
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Pharmalot
STAT+

Supreme Court might still hear another key case over biosimilars

  • Ed Silverman

By Ed Silverman Dec. 13, 2016

Reprints
drugs
Alex Hogan/STAT

The US Supreme Court may have declined to hear a case over a key rule involving the sale of biosimilars, but some attorneys said the court may review yet another similar case soon, especially since the US Solicitor General urged the justices to do so.

 

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Ed Silverman

Ed Silverman

Pharmalot Columnist, Senior Writer

Ed Silverman covers the pharmaceutical industry.

Tags

Will there be any emergency doctors to see you…
Will there be any emergency doctors to see you in the future?
Pharmalittle: Biden administration to fine drugmakers for price hikes…
Pharmalittle: Biden administration to fine drugmakers for price hikes on 27 meds; Dems push pharmacy chains…
The untold story of TV’s first prescription drug ad
The untold story of TV’s first prescription drug ad
‘We’re getting much more aggressive’: Microsoft’s Nuance adds GPT-4…
‘We’re getting much more aggressive’: Microsoft’s Nuance adds GPT-4 AI to its medical note-taking tool
Karuna’s treatment for schizophrenia achieves study goals, bolsters FDA…
Karuna’s treatment for schizophrenia achieves study goals, bolsters FDA filing plans
Hospitals are not crumbling, Medicare experts tell Congress
Hospitals are not crumbling, Medicare experts tell Congress

Recommended Stories